EGFR and non-small cell lung carcinoma: In our previous study, we retrospectively presented the later-line efficacy of dacomitinib on 11 patients with NSCLC harboring uncommon EGFR mutations, and the findings indicated a promising activity of dacomitinib (Li et al., 2022).